Results 71 to 80 of about 16,360 (195)

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis

open access: yes, 2009
Joseph R LuttDivision of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, Oregon, USAAbstract: The management of rheumatoid arthritis (RA) has undergone an impressive transformation over the past few decades.
Joseph R Lutt
core  

Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundWe examined the cardiovascular risk of abatacept compared with tumor necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus (DM). Methods and ResultsWe conducted a cohort study of patients with
Eun Ha Kang   +6 more
doaj   +1 more source

Peripheral targets for neuropathic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour   +3 more
wiley   +1 more source

Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.

open access: yes, 2019
Evaluate abatacept retention over 2 years in the AbataCepT In rOutiNe clinical practice (ACTION) study. ACTION was an international, observational study of patients with moderate-to-severe rheumatoid arthritis (RA) who initiated intravenous abatacept ...
Alten, Rieke   +21 more
core   +1 more source

Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production

open access: yesImmunological Medicine, 2020
Abatacept may exert its clinical effect on rheumatoid arthritis (RA) by suppressing anti-cyclic citrullinated peptide (CCP) antibody production. This study was undertaken to test this hypothesis by examining the changes of disease activity of RA and anti-
Hisakata Yamada   +14 more
doaj   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang   +4 more
wiley   +1 more source

Effect of abatacept treatment on the development of albuminuria and mesangial expansion.

open access: yes, 2016
A) 24h urinary albumin excretion rate values in diabetic mice treated with abatacept or vehicle show no statistically significant differences between abatacept-administered group and vehicle group. B) Delta urinary albumin excretion rate from baseline. C)
Lisbeth Nielsen Fink (199258)   +4 more
core   +1 more source

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis

open access: yesImmunological Medicine, 2019
The aim of this study was to assess abatacept in rheumatoid arthritis (RA) patient. Patients (20 men, 89 women, aged 61.9 ± 10.4 y) who responded inadequately to conventional synthetic disease-modifying anti-rheumatic drug were treated with abatacept for
Noriyoshi Ogawa   +14 more
doaj   +1 more source

The Place of Therapeutic Apheresis in Severe Immune‐Related Adverse Events: A Scoping Review of Literature

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 6, December 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the management of patients with cancer. However, they can induce breakdowns in immunologic tolerance, leading to autoimmune diseases, or immune related adverse events (irAEs). These irAEs can sometimes be life threatening, requiring aggressive management, such as immunosuppressant (IS) or
C. Vuillet   +36 more
wiley   +1 more source

Abatacept and the risk of malignancy:a meta-analysis across disease indications [PDF]

open access: yes
Objectives: To estimate the association between abatacept use and the incidence of malignancy excluding non-melanomatous skin cancers (NMSCs). Methods: Systematic database searches were performed, to April 2024, to identify phase II/III/IV randomized ...
Russell, Mark D.; id_orcid   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy